



Multiple myeloma: research update

Compiled by Myeloma Canada - September 2024



American Society of Clinical Oncology (ASCO) Annual Meeting - May 30 – June 3, 2024

European Hematology Association (EHA) Hybrid Congress - June 13-16, 2024

Myeloma Canada, along with thousands from the global hematology community, had the privilege of following the American Society of Clinical Oncology (ASCO) Annual Meeting (May 30 – June 3) and the European Hematology Association (EHA) Hybrid Congress (June 13-16) to hear from leading myeloma experts about the latest progress in myeloma research.

The focus of the myeloma research presented was on belantamab mafodotin (Belamaf, an antibody-drug conjugate), quadruplet therapies with either daratumumab (Darzalex) or isatuximab (Sarclisa) in both transplant-eligible and ineligible newly diagnosed myeloma, bispecific antibody treatments, and chimeric antigen receptor (CAR) T-cell therapies. The results presented are a major step toward the potential Health Canada approval of belantamab mafodotin for relapsed/refractory myeloma, as well as the establishment of quadruplet therapies as the standard of care in newly diagnosed myeloma. In addition, bispecific antibody therapies and CAR T-cell therapies continue to show great efficacy and promise for the treatment of relapsed/refractory myeloma.

I - For a non-exhaustive global overview of the myeloma research presented at both conferences, please consult the resources below by our sister myeloma organizations.

- **International Myeloma Foundation (IMF)**

- [Key Multiple Myeloma Abstracts Presented at 2024 ASCO and EHA Meeting](#)

- [Top Myeloma Research Presented at ASCO & EHA 2024](#)

- **Multiple Myeloma Research Foundation (MMRF)**

- Recap of the Latest Findings on Myeloma Treatments Reported at ASCO 2024

- Day 1: <https://themmrf.org/mmr-f-blogs/asco-2024-myeloma-oral-sessions/>
 - Day 2: <https://themmrf.org/mmr-f-blogs/asco-2024-myeloma-oral-sessions-day-2/>
 - Day 3: <https://themmrf.org/mmr-f-blogs/asco-2024-myeloma-oral-sessions-day-3/>

- [Recap of the latest findings on myeloma treatments reported at EHA 2024](#)

- **Myeloma Patients Europe (MPe)**

- [EHA 2024 Myeloma Highlights](#)



- **HealthTree Foundation for Multiple Myeloma**

— ASCO 2024

- [A Phoenix Rising as Blenrep Shows Positive Data in Multiple Myeloma](#)
- [New Hope for Newly Diagnosed Multiple Myeloma Patients](#)
- [BCMA-Directed Therapies in Relapsed Multiple Myeloma](#)

— EHA 2024

- [Bispecific Antibodies and New Advances in Myeloma Treatment](#)

II - For a more specific overview of the latest myeloma research presented at both conferences, below are some (non-exhaustive) resources we've compiled for you.

Newly diagnosed transplant eligible multiple myeloma:

- **PERSEUS Trial: Improved Depth of Response and MRD Negativity with Daratumumab (DARA) + bortezomib/lenalidomide/dexamethasone (VRd)**

Watch video: <https://youtu.be/35CKfud9QvU?si=tNqgwz5AY7mMKWMbc>

- **GMMG-HD7 Trial: Isatuximab, Lenalidomide, Bortezomib, and Dex for Newly-Diagnosed Multiple Myeloma**

Watch video: <https://youtu.be/XYkjjwJ4owfA?si=xJFi5WNdu0hK3WVA>

- **Phase I Study: Dual Targeting BCMA & CD19 FASTCAR-T for High-Risk Multiple Myeloma**

Watch video: <https://youtu.be/Jn5hDHaDREk?si=7RipqDjK6xnVG1qh>

Newly diagnosed transplant ineligible multiple myeloma:

- **IMROZ Trial: Isa-VRd vs VRd for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma**

Watch video 1: <https://youtu.be/WqP4GH8h3Qk?si=ZwLibJrBqQNHiw7>

- **BENEFIT Trial: Isatuximab + Len/Dex/Bortezomib vs IsaRd in Newly Diagnosed Transplant Ineligible Multiple Myeloma**

Watch video 2: <https://youtu.be/4n2U7agpVio?si=-amRnts1d-7PKk7l>

- **KarMMa-2 Study: Idecabtagene Vicleucel for High-Risk Early Relapse Multiple Myeloma**

Watch video: <https://youtu.be/f4Kv-pppbs4?si=WRA24jSKA0TFIbm4>



Relapsed/refractory multiple myeloma (RRMM):

- **DREAMM-7 Trial: Belamaf+Bvd vs DVd, analyses of phase 3 trial comparing regimens after relapse**

Watch video: https://youtu.be/IgxxVFYB1gw?si=Z_C8ZIkC0orrfH-O

- **DREAMM-8 Trial: Belantamab mafodotin + pomalidomide and dex shows improved outcomes in RRMM**

Watch video: <https://youtu.be/lwHdF112gnc?si=4ydluU9bnCQyrNIZ>

- **Cevostamab Shows Promise in Hard-to-Treat Multiple Myeloma: Early CAMMA 2 Trial Results**

Watch video: https://youtu.be/_QRTy3knbQ4?si=Vbaj6DaqtT7d0YtC

- **Efficacy, Safety, and Determination of ABBV-383, a BCMA Bispecific Antibody, in Patients with RRMM**

Watch video: https://youtu.be/ChRZU_uxPvQ?si=2S36FwPcx5Cpi4H1

- **MajesTEC-1 Trial: Longer Follow-up Teclistamab + Tocilizumab Prophylaxis for CRS in RRMM**

Watch video: https://youtu.be/i3ryVOK_z6o?si=V0042IOpUYWSVvkQ0

- **LINKER-MM1 Trial: Linvoseltamab for RRMM: Deep, Durable Responses at 14-Month Follow-Up**

Watch video: <https://youtu.be/R6grWC0r8ZE?si=Ut0aEPsGjr9m-as->

- **MagnetisMM-30, a Phase 1b Study of Elranatamab (ELRA) and Iberdomide (IBER) Combination in RRMM**

Watch video: <https://youtu.be/2kGLdACW4Oo?si=gP3wTbdCt3r6RHxb>

